title: Cellular Vaccines Modified with Hyper IL6 or Hyper IL11 Combined with Docetaxel in an Orthotopic Prostate Cancer Model.
abstract: BACKGROUND
  Whole-cell-based vaccines modified with Hyper-IL-6 (H6) and Hyper-IL-11 (H11) have demonstrated high activity in murine melanoma and renal cancer models.
  
  
  METHODS
  H6 and H11 cDNA was transduced into TRAMP cells (TRAMP-H6 and TRAMP-H11). An orthotopic TRAMP model was employed. The efficacy of TRAMP-H6 and TRAMP-H11 in combination with docetaxel was evaluated. Immune cells infiltrating tumors were assessed.
  
  
  RESULTS
  Immunization with TRAMP-H6 and TRAMP-H11 vaccines extended OS of mice. Addition of docetaxel to TRAMP-H6 and TRAMP-H11 vaccines further extended OS of the animals. Vaccination with TRAMP-H6 alone and TRAMP-H11 combined with docetaxel augmented tumor infiltration by activated CD8(+) and CD4(+) T-cells and attracted higher number of activated, mature DCs infiltrating tumors. Addition of docetaxel to TRAMP-H6, TRAMP-H11, TRAMP-Adv700 vaccines enhanced the infiltration of the tumor by NK cells.
  
  
  CONCLUSIONS
  Addition of docetaxel to modified TRAMP vaccines improved clinical benefit of treated mice and enhanced anti-tumor immune response.
authors.affiliation: Medical Biotechnology, University of Medical Sciences, Poznan, Poland Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, Poznan, Poland Department of Medical and Experimental Oncology, Clinical Hospital of Poznan University of Medical Sciences, Poznan, Poland jmackiewicz@ump.edu.pl.
authors.forename: Jacek
authors.initials: J
authors.lastname: Mackiewicz
authors.affiliation: Medical Biotechnology, University of Medical Sciences, Poznan, Poland.
authors.forename: Urszula
authors.initials: U
authors.lastname: Kazimierczak
authors.affiliation: Medical Biotechnology, University of Medical Sciences, Poznan, Poland.
authors.forename: Marek
authors.initials: M
authors.lastname: Kotlarski
authors.affiliation: Medical Biotechnology, University of Medical Sciences, Poznan, Poland.
authors.forename: Ewelina
authors.initials: E
authors.lastname: Dondajewska
authors.affiliation: Medical Biotechnology, University of Medical Sciences, Poznan, Poland.
authors.forename: Anna
authors.initials: A
authors.lastname: Kozłowska
authors.affiliation: Medical Biotechnology, University of Medical Sciences, Poznan, Poland Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, Poznan, Poland.
authors.forename: Eliza
authors.initials: E
authors.lastname: Kwiatkowska
authors.affiliation: Medical Biotechnology, University of Medical Sciences, Poznan, Poland.
authors.forename: Anita
authors.initials: A
authors.lastname: Nowicka-Kotlarska
authors.affiliation: Medical Biotechnology, University of Medical Sciences, Poznan, Poland Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, Poznan, Poland.
authors.forename: Hanna
authors.initials: H
authors.lastname: Dams-Kozłowska
authors.affiliation: Medical Biotechnology, University of Medical Sciences, Poznan, Poland.
authors.forename: Piotr Jan
authors.initials: PJ
authors.lastname: Wysocki
authors.affiliation: Medical Biotechnology, University of Medical Sciences, Poznan, Poland Department of Diagnostics and Cancer Immunology, Greater Poland Cancer Centre, Poznan, Poland BioContract Sp z o.o., Poznan, Poland.
authors.forename: Andrzej
authors.initials: A
authors.lastname: Mackiewicz
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000235:genetics / Q000276:immunology; D004195:Disease Models, Animal; D000077143:Docetaxel; D006801:Humans; D007167:Immunotherapy; D017370:Interleukin-11 / Q000008:administration & dosage / Q000235:genetics*; D015850:Interleukin-6 / Q000008:administration & dosage / Q000235:genetics*; D007694:Killer Cells, Natural / Q000276:immunology; D008297:Male; D051379:Mice; D014411:Neoplastic Stem Cells / Q000276:immunology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000276:immunology; D043823:Taxoids / Q000008:administration & dosage
chemical_list: D019496:Cancer Vaccines; C508611:IL11 protein, human; C508600:IL6 protein, human; D017370:Interleukin-11; D015850:Interleukin-6; D011993:Recombinant Fusion Proteins; D043823:Taxoids; D000077143:Docetaxel
keywords: Cancer vaccine; docetaxel; immunotherapy; murine model; prostate cancer